• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Quarterly Sales Slip Might Change The Case For Investing In Adaptive Biotechnologies (ADPT)

    Simply Wall St·11/05/2026 11:43:45
    Listen to the news
    • Adaptive Biotechnologies reported third quarter 2026 sales of US$83.9 million, down from US$93.97 million a year earlier, with net income of US$2.88 million compared with US$9.55 million and basic and diluted EPS from continuing operations of US$0.02 versus US$0.06.
    • Across the first nine months of 2026, Adaptive Biotechnologies generated sales of US$226.33 million compared with US$205.3 million but reported a larger net loss of US$56.95 million versus US$45.92 million, indicating that higher revenue was accompanied by increased expenses.
    • This sets the context for assessing how Adaptive Biotechnologies' investment narrative aligns with the softer quarterly earnings, particularly the smaller third quarter profit.
    Position your portfolio for where healthcare is heading by comparing Adaptive Biotechnologies with a hand picked 38 healthcare AI stocks that harness data, immunology and AI in different ways.

    Adaptive Biotechnologies Investment Narrative Recap

    To hold Adaptive Biotechnologies in a portfolio, you need to believe its MRD engine and Immune Medicine platform can turn growing clinical adoption and pharma demand into durable profitability. The latest quarter showed softer earnings and a smaller profit, so the near term focus stays squarely on execution and cost discipline rather than headline growth.

    Right now, the most important short term catalyst is whether MRD volumes and pharma trial work continue to support healthier mix and margins through the rest of 2026. The biggest risk is that rising operating costs in Immune Medicine, combined with any pricing or reimbursement headwinds in clonoSEQ, keep consolidated losses elevated.

    The third quarter 2026 earnings release is the key data point to watch here. Revenue across the first nine months of 2026 reached US$226.33 million, while the company reported a larger net loss of US$56.95 million compared with the prior year period. That combination puts the spotlight on expense control and how quickly Adaptive Biotechnologies can scale MRD profitability.

    For investors tracking catalysts, those numbers feed directly into expectations that MRD can support better margins while Immune Medicine is reshaped around TCR antigen data and AI models. The risk side of that equation is clear. If new high margin pharma partnerships in Immune Medicine are slow to materialise or MRD reimbursement metrics soften, the path to improved earnings could prove bumpier than hoped.

    On these analyst assumptions, Adaptive Biotechnologies is modeled to reach about US$484.0 million in revenue and US$18.3 million in earnings by 2029. This implies forecast revenue growth of 16.2% per year and an earnings swing of roughly US$82.2 million from a loss of US$63.9 million today.

    Discover how Adaptive Biotechnologies' fair value indicates a 13% potential upside to its current price that may not last much longer.

    NasdaqGS:ADPT 1-Year Stock Price Chart
    NasdaqGS:ADPT 1-Year Stock Price Chart

    Exploring Other Perspectives

    One bullish twist to consider focuses on MRD profitability. The most optimistic analysts were expecting Adaptive Biotechnologies to reach about US$519.4 million in revenue and US$34.9 million in earnings by 2029 before this softer third quarter. That outlook presents a far more upbeat earnings arc and it shows how sharply opinions can differ, so treat this latest report as a prompt to compare several narratives rather than rely on a single view.

    Explore 3 other Adaptive Biotechnologies fair value estimates, including one that suggests as much as 31% upside from the current price.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more investment ideas beyond Adaptive Biotechnologies?

    If Adaptive Biotechnologies has sharpened your thinking about where precision medicine and data driven healthcare might head next, you can use that same framework to scan the wider market. The Simply Wall St Screener lets you filter by quality, valuation, balance sheet strength and income profile so you can build a watchlist that matches your objectives.

    • If capital preservation comes first for you, you might start with a group of 31 resilient stocks with low risk scores that have historically been less volatile and may help steady the overall portfolio.
    • For investors looking for potentially mispriced quality, you can consider using the Screener to surface a curated 19 high quality undiscovered gems that combine sound fundamentals with relatively low market attention.
    • If income is a core part of your plan, you can focus on a selection of 5 dividend fortresses that offer higher yields while still passing basic fundamental checks.